|
Q3 FY2026
As of Sep 30, 2026
|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
|
|---|---|---|---|---|
| ASSETS | ||||
| Cash and due from banks | ||||
| Restricted cash | ||||
| Interest-bearing due from banks | ||||
| Cash and cash equivalents | ||||
| Securities Purchased under Agreements to Resell | ||||
| Securities available-for-sale, at fair value | ||||
| Securities held-to-maturity (fair value of $2.4 billion and $2.6 billion, net of allowance for credit losses of $1.7 million and $1.7 million at Dec. 31, 2025 and 2024, respectively) | ||||
| Consumer loans held-for-sale | ||||
| Federal funds sold, securities purchased under resale agreements, and interest earning deposits with banks | ||||
| Total cash, cash equivalents, and restricted cash | ||||
| Investment securities held to maturity, net | ||||
| Investment securities available for sale | ||||
| Loans held for sale (includes $28 million at fair value as of Sep 30, 2026 and none at fair value as of Dec 31, 2025) | ||||
| Financing Receivable, before Allowance for Credit Loss | ||||
| Financing Receivable, Allowance for Credit Losses | ||||
| Financing Receivable, after Allowance for Credit Loss | ||||
| Premises and equipment, net | ||||
| Equity method investment | ||||
| Accrued interest receivable | ||||
| Loans, net of deferred fees and costs | ||||
| Allowance for loan losses | ||||
| Loans, net | ||||
| Premises, equipment, and software, net | ||||
| Cash surrender value of bank-owned life insurance | ||||
| Goodwill | ||||
| Core deposits and other intangible assets | ||||
| Other real estate owned | ||||
| Core deposits and other intangible assets, net | ||||
| Other assets | ||||
| Total assets | ||||
| LIABILITIES AND EQUITY | ||||
| Liabilities | ||||
| Deposits: | ||||
| Non-interest-bearing | ||||
| Interest-bearing | ||||
| Savings and money market accounts | ||||
| Time Deposits | ||||
| Total deposits | ||||
| Securities sold under agreements to repurchase | ||||
| Federal Home Loan Bank advances | ||||
| Subordinated debt and other borrowings | ||||
| Accrued interest payable | ||||
| Non-interest-bearing deposits | ||||
| Interest-bearing deposits | ||||
| Total deposits | ||||
| Federal funds purchased and securities sold under repurchase agreements | ||||
| FHLB advances and other borrowings | ||||
| Other liabilities | ||||
| Total liabilities | ||||
| Equity | ||||
| Shareholders' equity: | ||||
| Preferred stock, no par value; 10.0 million shares authorized; 225,000 shares non-cumulative perpetual preferred stock, Series B, liquidation preference $225.0 million, issued and outstanding at Dec. 31, 2025 and 2024, respectively | ||||
| Common stock, par value $1.00; 180.0 million shares authorized; 77.7 million and 77.2 million shares issued and outstanding at Dec. 31, 2025 and 2024, respectively | ||||
| Preferred stock — no par value per share, liquidation preference 225 million non-cumulative perpetual preferred stock, Authorized — 110 million shares at Jun 30, 2026 and 10 million shares at Dec 31, 2025, Issued and outstanding — 22 million shares at Sep 30, 2026 and 225,000 shares at Dec 31, 2025 | ||||
| Common stock — $1.00 par value, Authorized — 360 million shares at Jun 30, 2026 and 180 million shares at Dec. 31, 2025, Issued and outstanding — 151 million shares at Sep 30, 2026 and 78 million at Dec 31, 2025 | ||||
| Additional paid-in capital | ||||
| Accumulated other comprehensive income (loss), net | ||||
| Retained earnings | ||||
| Total equity | ||||
| Total liabilities and equity |
Loading...